Psoriasis. Definition and causes Definition and causes Types Types GP management GP management Pitfalls Pitfalls Hospital treatments Hospital treatments.

Slides:



Advertisements
Similar presentations
Epidemiology, presentation, complication and management.
Advertisements

IDENTIFICATION AND MANAGEMENT
Ramesh Mehay Programme Director (Bradford VTS)
Dermatology in General Practice
Psoriasis. Definition Chronic plaque psoriasis (psoriasis vulgaris) is a chronic inflammatory skin disease characterised by well demarcated erythematous.
Acne What is acne? Symptoms Causes WWHAM Medical treatment Counselling.
Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open label study Jacobi A et al. One of authors Braeutigam M belongs to clinical.
Psoriasis By Sandra E. Valenzuela 5/5/02 Definition A Chronic (long lasting) skin disease characterized by scaling and inflammation. Scaling occurs when.
Psoriasis Definition: is a chronic, sometimes acute, non- contagious common condition of the skin Definition: is a chronic, sometimes acute, non- contagious.
Biologics in psoriasis (2008) Dr. Amal Kokandi. What are biologics?  "biologics" are made from human or animal proteins. Biologics have been in use for.
Pharmacology-4 PHL 425 Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:
Psoriasis: Treatment and Management Ann Davies Clinical Nurse Specialist in Dermatology University Hospital Of Wales, Cardiff.
Agents Used in the Treatment of Skin Disorders
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Introduction to Psoriasis Denise Cook, M.D. Medical Officer Division of Dermatology.
Psoriasis & Skin Cancer
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, PsoriasisPsoriasis.
PSORIASIS. Psoriasis is a disease which affects the skin and joints. Psoriasis is a disease which affects the skin and joints.skinjointsskinjoints It.
BADBIR BAD Biologic Interventions Register Dr Kathy McElhone 27 th June 2012.
Psoriasis and Skin Cancer Edward Pritchard. Long Cases You could get these! Last year’s finals! - Patient with recurrent SCC, with no symptoms. History.
Papulosquamous diseases Dr. Fahad AlSaif Consultant & Associated Professor Chairman of Dermatology Department.
Psoriasis By Anna Hodge Objectives Recognise psoriasis Know the first line treatments for psoriasis Use topical corticosteroids safely Know.
Psoriasis By: Angie Vasquez and Marsa Eglip. Introduction Basic description of psoriasis Basic description of psoriasis Symptoms Symptoms Genetic cause.
SHRI GANASAYA NAMAHA. AN UPDATE ON PSORIASIS BY DR. MAHESH MATHUR, MD,DVD,DCP (UK) MD,DVD,DCP (UK)
Psoriasis. Definition and causes Types GP management Pitfalls Hospital treatments Case studies.
BAD Biologic Interventions Register (BADBIR ) An update November 2010.
A Red Scaly Rash Small Group Teaching Problem Based Learning Dermatology Department College of Medicine King Saud University.
1 PsoriasisPsoriasis Dr. Majdy Naim. 2 PrevalencePrevalence Psoriasis occurs in 2% of the world’s population Psoriasis occurs in 2% of the world’s population.
Alexandra Pyle Bsc (Hons) Registered Nurse. What is Psoriasis?  Psoriasis is a chronic inflammatory skin disorder characterised by thickened, scaly plaques.
Psoriasis. Definition and causes Types GP management Pitfalls Hospital treatments.
Slow Acting Anti-inflammatory Drugs. DEFINITION Drugs used to relief pain & inflammation.
Psoriasis Dr. Lyn Guenther, MD FRCPC Professor of Dermatology UW O Medical Director, The Guenther Dermatology Research Centre.
 exact cause unknown  defect of the skin that impairs its function as a barrier, combined with an abnormal function of the immune system, are believed.
PSORIASIS Ben Basger Basgers Pharmacy North Bondi Pharmacy Practice, The University of Sydney.
Psoriasis and Other Papulosquamous Disease. Definitions – Psoriasis is the most common chronic papulosquamous disease – The classic lesion of psoriasis.
BAD Biologic Interventions Register (BADBIR ) An update November 2009.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Eczema & Psoriasis Dr. Jerald E. Hurdle Kennebec Medical Consultants Waterville, ME
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Disease modified Anti-rheumatic drugs ( DMARD)
Psoriasis  Clinical manifestations. There are two major types: 1.Eruptive, inflammatory type with multiple small guttate lesions and a greater tendency.
PSORIASIS BY: Jennifer Teen Health 8 Old Orchard Junior High School.
Chapter 5 Psoriasis.
Psoriasis and Other Papulosquamous Disease
Diagnosis and Management of Psoriasis and Psoriatic Arthritis
How can pharmacists help improve outcomes for patients with psoriasis?
Psoriasis.
By AFSAR FATHIMA Dept. of Pharmacology
Role of topical corticosteroids in the treatment of AD and psoriasis
Diagnosis and treatment algorithm for psoriasis
Psoriasis John Sugrue.
Department of Dermatology
An Introduction to Topical Therapies
Psoriasis داء الصدفية.
Retinoids used in dermatology
Psoriasis Tutoring By Alaina darby.
treatment of psoriasis (Evidence -based Dermatology) H.Mozayyeni
Psoriasis and Skin Cancer
WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in
Skin Conditions II. Skin Conditions II Corn and Calluses.
Dermatology update in common cases and treatment
Clive Tubb CNS Dermatology
Kate Blake Lead Nurse Dermatology
Presentation transcript:

Psoriasis

Definition and causes Definition and causes Types Types GP management GP management Pitfalls Pitfalls Hospital treatments Hospital treatments Psoriasis

Psoriasis Definition A chronic, non-infectious, inflammatory skin disorder, with well defined, erythematous plaques & large adherent silvery scales Prevalence 1.5-3% Age onset 20-30y or 50-60y

Psoriasis Epidermal hyperproliferation Vascular dilatation Inflammatory infiltrate

What causes psoriasis ? T cell mediated autoimmune disease → increased keratinocyte proliferation Environmental and genetic factors

Psoriasis Genetics 40% have FHx 40% have FHx 73% monozygotic twins concordant v 20% dizygotic twins 73% monozygotic twins concordant v 20% dizygotic twins 1 st degree relatives have 4-6 fold increased risk 1 st degree relatives have 4-6 fold increased risk Environmental triggers Environmental triggers

GP Management Time (for proper examination and to communicate with the patient) Explanation Information and support sources (patient.co.uk, psoriasis- association.org.uk) Follow-up

Emollients Emollients Bath oils Bath oils Site-specific topical treatments Site-specific topical treatments GP Management

Vitamin D analogues Dovonex (calcipotriol) oint Dovobet (calcipotriol & betamethasone) oint or gel Silkis (calcitriol) oint Curatorderm (tacalcitol) oint & lotion Zorac (tazarotene) gel (retinoid) Vitamin D analogues Dovonex (calcipotriol) oint Dovobet (calcipotriol & betamethasone) oint or gel Silkis (calcitriol) oint Curatorderm (tacalcitol) oint & lotion Zorac (tazarotene) gel (retinoid) Dovonex cream and scalp application no longer available Dovonex cream and scalp application no longer available Topical treatments

Tar Carbo-dome Exorex Psoriderm Alphosyl HC Sebco Cocois Tar-based bath oils & shampoos Tar Carbo-dome Exorex Psoriderm Alphosyl HC Sebco Cocois Tar-based bath oils & shampoos Topical treatments

Steroids Often in conjunction with Vit D analogue as Dovobet or separate steroid Eumovate (only oint available) Trimovate Scalp preparations (eumovate to dermovate strength) Steroids Often in conjunction with Vit D analogue as Dovobet or separate steroid Eumovate (only oint available) Trimovate Scalp preparations (eumovate to dermovate strength) BE CAREFUL (but not mean) BE CAREFUL (but not mean) Topical Treatments

Dithranol Dithrocream Micanol Psorin Dithranol Dithrocream Micanol Psorin Stains skin Has to be washed off Start and low strength and build up Stains skin Has to be washed off Start and low strength and build up Topical Treatments

Topical treatments Nails difficult potent topical steroids dovonex tazarotene systemic therapy

Scalp Remove scale first Remove scale first Sebco messy but effective Sebco messy but effective Tar or salicylic acid shampoo Tar or salicylic acid shampoo Topical steroids if necessary for short periods Topical steroids if necessary for short periods Topical Treatments

Types of psoriasis Plaque Guttate Rupioid Unstable Pustular Erythrodermic ?palmo-plantar pustulosis

Guttate psoriasis

Pustular psoriasis

Erythrodermic psoriasis

Plantar pustulosis

Acrodermatitis continua of Hallopeau

'It's not working Doc' 'It's not working Doc' It did work, but then he stopped using it and the psoriasis returned It did work, but then he stopped using it and the psoriasis returned It was too greasy/time- consuming/smelly so he stopped using it It was too greasy/time- consuming/smelly so he stopped using it He wasn't applying it properly He wasn't applying it properly It really didn't work It really didn't work Pitfalls

Hospital Treatment Out-patient advice and support UVB PUVA Acitretin Methotrexate Ciclosporin Biologics Admission (tar, other topicals)

UVB phototherapy Suitability – age, PH skin cancer, medication, radiotherapy, photosensitive disease X3 / week for ~6 weeks Shield genitalia, uninvolved sites SE burning (30%) ↑ risk skin cancer (screen yearly if >150 treatments)

PUVA Suitability – as for UVB + CI in renal/hepatic disease, cataracts, pregnancy, children X2 / week for ~6-8 weeks Need eye protection for 24 h after psoralen SE burning, nausea, itch ↑ risk skin cancer (screen yearly if >150 treatments)

Systemic therapy acitretin methotrexate ciclosporin

7-20% of patients with psoriasis have arthritis

Acitretin mec: affects keratinocyte differentiation CI: ? fertile women (as must avoid pregnancy for 2 years) SE: dry lips, teratogenicity, abnormal LFT, lipids, DISH

Methotrexate mec: inhibits DNA synthesis by inhibiting dihydrofolate reductase → reduces proliferation of lymphocytes + keratinocytes CI: pregnancy, lactation, infection, liver/renal disease, peptic ulcers SE: anorexia, nausea, myelosuppression, hepatotoxicity, mouth ulcers, pulmonary toxicity, oligospermia, skin cancer Interactions: NSAIDs, septrin, trimethoprim, penicillin, phenytoin Given once a WEEK

Ciclosporin Mec Inhibits T cell activation CI uncontrolled HBP, malignancy, infection SE HBP, nephrotoxicity, skin cancer, other malignancy, gum hypertrophy Not recommended for long term treatment

New Biologicals Anti TNF drugs Infliximab, etanercept, adalimumab Targeted T - cell therapy alefacept (binds CD2 & blocks LFA3) efalizumab (binds to LFA-1 & blocks ICAM-1) Anti-IL 17 receptor antibodies Brodalumab Ixekizumab

Know what your patient is on (?record as outside script on EMIS) Know what your patient is on (?record as outside script on EMIS) Know what monitoring you are responsible for Know what monitoring you are responsible for Keep a look out for myelosuppression Keep a look out for myelosuppression Don't be afraid of your local Derm department! Don't be afraid of your local Derm department! GP Issues

SIGN 121 Patients with psoriasis or psoriatic arthritis should have an annual review with their GP involving the following: documentation of severity using DLQI ƒscreening for depression ƒassessment of vascular risk (in patients with severe disease) ƒassessment of articular symptoms ƒoptimisation of topical therapy ƒconsideration for referral to secondary care